Esperion Therapeutics, Inc.ESPRNASDAQ
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank86
3Y CAGR+11.0%
Year-over-Year Change
Year-over-year free cash flow growth rate
3Y CAGR
+11.0%/yr
Annual compound
Percentile
P86
Within normal range
vs 3Y Ago
1.4x
Solid growth
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 46.17% |
| 2024 | 82.31% |
| 2023 | 22.50% |
| 2022 | 33.73% |
| 2021 | -167.70% |
| 2020 | -38.22% |
| 2019 | 52.08% |
| 2018 | -13.30% |
| 2017 | -174.59% |
| 2016 | -24.28% |